1. Web alert

   • John Carwile, MD Sadler Clinic, 508 Medical Center Blvd., Conroe, TX 77304, USA. E-mail: jcarwile@sadler.com

   EditorialNotes 01 May 2007 Pages: 65 - 65

2. Genomic instability: The cause and effect of BCR/ABL tyrosine kinase

   • Tomasz Skorski

   OriginalPaper 01 May 2007 Pages: 69 - 74

3. BCR-ABL-negative chronic myeloid leukemia

   • Sonja Burgstaller
   • Andreas Reiter
   • Nicholas C. P. Cross

   OriginalPaper 01 May 2007 Pages: 75 - 82

4. Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia

   • Ronan Swords
   • Yesid Alvarado
   • Francis J. Giles

   OriginalPaper 01 May 2007 Pages: 83 - 88

5. Immunotherapeutic strategies in chronic myeloid leukemia

   • Richard E. Clark

   OriginalPaper 01 May 2007 Pages: 89 - 94

6. Antibiotic prophylaxis during chemotherapy-induced neutropenia for patients with acute leukemia

   • Sarah P. Hammond
   • Lindsey R. Baden

   OriginalPaper 01 May 2007 Pages: 97 - 103

7. What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?

   • István Molnár
   • Bayard L. Powell

   OriginalPaper 01 May 2007 Pages: 104 - 110

8. New approaches for the detection of minimal residual disease in acute myeloid leukemia

   • Anna van Rhenen
   • Bijan Moshaver
   • Gerrit Jan Schuurhuis

   OriginalPaper Open access 01 May 2007 Pages: 111 - 118

9. Role of autologous stem cell transplantation in multiple myeloma

   • Shaji Kumar

   OriginalPaper 01 May 2007 Pages: 121 - 127

10. Current status of bortezomib in the treatment of multiple myeloma

    • Michele Cavo

    OriginalPaper 01 May 2007 Pages: 128 - 137